| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_217da536f1bd19d480d1b5862c75044f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-482 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-75 |
| filingDate |
2017-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_161b0a914b9966482e332cc9668db3f5 |
| publicationDate |
2019-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3463311-A1 |
| titleOfInvention |
Compositions and methods for thromboembolism dissolution |
| abstract |
Disclosed herein are novel thrombolytic formula for safe and effective treatment of blood clots. In clinical trials, cats of various breeds and ages presented partial or full paralysis of one or more limbs, due to arterial thromboembolism (ATE). Average treatment ranged from 3 days to 2 weeks, depending on the clot size and time elapsed since clot was dislodged from the subject's heart. These are significant findings considering the lack of treatment options available in veterinary medicine for cats with HCM and ATE. Veterinarians often euthanize cats presenting ATE, as no safe and effective thrombolytic agent is currently available for veterinary use. Previous thrombolytics were shown to have an average mortality rate of 60% due to reperfusion injury and hemorrhaging. The disclosed formula, on the other hand, overcomes these shortcomings. |
| priorityDate |
2016-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |